Carnegie acted as joint bookrunner in the fully guaranteed SEK 150 million rights issue and potential over-allotment option of up to approximately SEK 30m in Isofol. Isofol Medical is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. June 2020.
Healthcare
Rights issue in Isofol Medical AB (SE) — SEK 150 million
June 2020